{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T05:06:37Z","timestamp":1789189597977,"version":"build-2803163510"},"reference-count":32,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2014,3,7]],"date-time":"2014-03-07T00:00:00Z","timestamp":1394150400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2014,5]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>This phase <jats:styled-content style=\"fixed-case\">II<\/jats:styled-content> study evaluated the safety and efficacy of lenalidomide in combination with rituximab in patients with relapsed\/refractory, indolent non\u2010<jats:styled-content style=\"fixed-case\">H<\/jats:styled-content>odgkin lymphoma (<jats:styled-content style=\"fixed-case\">NHL<\/jats:styled-content>). Patients were treated with daily lenalidomide in 28\u2010d cycles and weekly rituximab for 4\u00a0weeks. Lenalidomide was continued until progression or unacceptable toxicity. Twenty\u2010two patients were assessed for <jats:italic><jats:styled-content style=\"fixed-case\">FCGR<\/jats:styled-content>3<jats:styled-content style=\"fixed-case\">A<\/jats:styled-content><\/jats:italic> polymorphisms. Thirty patients were enrolled; 27 were evaluable for response. The overall response rate (<jats:styled-content style=\"fixed-case\">ORR<\/jats:styled-content>) was 74% including 44% complete responses (<jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content>); median progression\u2010free survival (<jats:styled-content style=\"fixed-case\">PFS<\/jats:styled-content>) was 12\u00b74\u00a0months. The 13 rituximab refractory patients had an <jats:styled-content style=\"fixed-case\">ORR<\/jats:styled-content> of 61\u00b75% (four <jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content>\/unconfirmed <jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content>). The <jats:styled-content style=\"fixed-case\">ORR<\/jats:styled-content> was 77% in the 22 follicular lymphoma patients (nine <jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content>\/unconfirmed <jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content>). At a median follow\u2010up time of 43\u00a0months, the median duration of response and time to next therapy were 15\u00b74 and 37\u00b74\u00a0months, respectively. Most common grade 3\/4 adverse events were lymphopenia (45%), neutropenia (55%), fatigue (23%) and hyponatraemia (9%). The <jats:styled-content style=\"fixed-case\">ORR<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">PFS<\/jats:styled-content> in patients with low\u2010affinity <jats:italic><jats:styled-content style=\"fixed-case\">FCGR<\/jats:styled-content>3<jats:styled-content style=\"fixed-case\">A<\/jats:styled-content><\/jats:italic> polymorphisms (<jats:styled-content style=\"fixed-case\">F<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">F<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">F<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">V<\/jats:styled-content>) suggest that lenalidomide may improve the activity of rituximab in these patients. These data suggest that combining lenalidomide with rituximab can produce durable responses with acceptable toxicity in patients with indolent <jats:styled-content style=\"fixed-case\">NHL<\/jats:styled-content>.<\/jats:p>","DOI":"10.1111\/bjh.12755","type":"journal-article","created":{"date-parts":[[2014,3,7]],"date-time":"2014-03-07T13:16:48Z","timestamp":1394198208000},"page":"375-381","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":71,"title":["Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non\u2010<scp>H<\/scp>odgkin lymphoma"],"prefix":"10.1111","volume":"165","author":[{"given":"Joseph M.","family":"Tuscano","sequence":"first","affiliation":[{"name":"UC Davis Cancer Center Sacramento CA USA"},{"name":"Veteran's Administration Northern California Healthcare System Martinez CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mrinal","family":"Dutia","sequence":"additional","affiliation":[{"name":"UC Davis Cancer Center Sacramento CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Chee","sequence":"additional","affiliation":[{"name":"California Cancer Care San Mateo CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Brunson","sequence":"additional","affiliation":[{"name":"UC Davis Cancer Center Sacramento CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Reed\u2010Pease","sequence":"additional","affiliation":[{"name":"UC Davis Cancer Center Sacramento CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehrdad","family":"Abedi","sequence":"additional","affiliation":[{"name":"UC Davis Cancer Center Sacramento CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanna","family":"Welborn","sequence":"additional","affiliation":[{"name":"UC Davis Cancer Center Sacramento CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert T.","family":"O'Donnell","sequence":"additional","affiliation":[{"name":"UC Davis Cancer Center Sacramento CA USA"},{"name":"Veteran's Administration Northern California Healthcare System Martinez CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,3,7]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.3.1110"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.3.754"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_8_5_1","first-page":"2644","article-title":"Combination immunotherapy of relapsed or refractory low\u2010grade or follicular non\u2010Hodgkin's lymphoma with rituximab and interferon\u2010\u03b1\u20102a","volume":"6","author":"Davis T.A.","year":"2000","journal-title":"Clinical Cancer Research"},{"key":"e_1_2_8_6_1","first-page":"367","article-title":"Lenalidomide overcomes FCRG3A\u2010mediated resistance to rituximab in patients with relapsed\/refractory indolent non\u2010Hodgkin's lymphoma: a correlative analysis of a phase 2 study","volume":"116","author":"Dutia M.","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_8_7_1","first-page":"15s","article-title":"Complete response rates with lenalidomide plus rituximab for untreated indolent B\u2010cell non\u2010Hodgkin's lymphoma","volume":"28","author":"Fowler N.H.","year":"2010","journal-title":"Journal of Clinical Oncology (ASCO Annual Meeting Abstracts)"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03535.x"},{"key":"e_1_2_8_9_1","first-page":"1687","article-title":"Treatment of MCL cells with combined rituximab and lenalidomide enhances NK\u2010mediated synapse formation and cell killing","volume":"114","author":"Gaidarova S.","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_8_10_1","first-page":"3441","article-title":"Lenalidomide alone and in combination with rituximab enhances NK cell immune synapse formation in chronic lymphocytic leukemia (CLL) cells in vitro through activation of Rho and Rac1 GTPases","volume":"114","author":"Gaidarova S.","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_8_11_1","first-page":"3723","article-title":"Anti\u2010proliferative and apoptotic activity of lenalidomide in combination with rituximab in follicular lymphoma: an in vitro and ex vivo analysis in follicular lymphoma cells","volume":"114","author":"Gandhi A.K.","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605349"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-0577"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0016"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-03-1091"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-133108"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23890"},{"key":"e_1_2_8_18_1","first-page":"437","article-title":"Optimizing the treatment of patients with rituximab\u2010pretreated recurrent indolent non\u2010Hodgkin lymphoma","volume":"6","author":"Leonard J.P.","year":"2008","journal-title":"Clinical Advances in Hematology and Oncology"},{"key":"e_1_2_8_19_1","first-page":"8000","article-title":"CALGB 50401: a randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma","volume":"30","author":"Leonard JP.","year":"2012","journal-title":"Journal of Clinical Oncology (ASCO Annual Meeting Abstracts)"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.5376"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.5827"},{"key":"e_1_2_8_22_1","first-page":"2427","article-title":"Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug","volume":"118","author":"Ramsay A.G.","year":"2008","journal-title":"The Journal of Clinical Investigation"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-217687"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06841.x"},{"key":"e_1_2_8_25_1","first-page":"1645","article-title":"Results of a phase II study of lenalidomide in combination witrh rituximab for the treatment of indolent non\u2010follicular non\u2010Hodgkin's lymphoma","volume":"120","author":"Sacchi S.","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_8_26_1","first-page":"8030","article-title":"High response rates with lenalidomide plus rituximab for untreated indolent B\u2010cell non\u2010Hodgkin lymphoma, including those meeting GELF criteria","volume":"29","author":"Samaniego F.","year":"2011","journal-title":"Journal of Clinical Oncology (ASCO Annual Meeting Abstracts)"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(89)90015-9"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.05.013"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.1169"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4405"},{"key":"e_1_2_8_31_1","first-page":"2612","article-title":"Direct inhibitory effects of lenalidomide on the proliferation and VEGF production of non\u2010Hodgkin lymphoma cells are associated with increased SPARC expression [abstract]","volume":"112","author":"Zhang L.H.","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21468"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2011.02.001"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.12755","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.12755","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T17:05:30Z","timestamp":1696352730000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.12755"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,7]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["10.1111\/bjh.12755"],"URL":"https:\/\/doi.org\/10.1111\/bjh.12755","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,7]]},"assertion":[{"value":"2013-08-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-11-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-03-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}